<!DOCTYPE html><html><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Allen Peng</title>
<link rel="stylesheet" href="https://use.typekit.net/vxy8tas.css">
<link rel="stylesheet" href="https://use.typekit.net/jge8wgr.css">
<meta property="og:title" content="Allen Peng">
<meta name="description" content="The homepage of Allen Peng">
<meta property="og:description" content="The homepage of Allen Peng">
<meta property="og:image" content="https://allen-peng-yl.github.io/images/profile.jpg">
<meta name="twitter:card" content="summary_large_image">
<link rel="preload" as="fetch" crossorigin="anonymous" href="/_payload.json?61f5057a-a3b8-43c4-85fe-5e07202c39e3">
<style>body{background-color:#f6f6f5;color:#303030;font-family:proxima-nova,sans-serif}h2{font-family:factoria,sans-serif;font-size:20pt;font-weight:700}a{color:#303030;cursor:pointer;position:relative;text-decoration:none;white-space:nowrap}a,a:after{transition:all .5s cubic-bezier(0,.8,.13,1)}a:after{background-color:#f3cfc6bb;bottom:0;content:"";left:-.1em;position:absolute;right:-.1em;top:66%;z-index:-1}@media (hover:hover){a:hover{color:#fff}a:hover:after{background-color:#9f2b68;top:0}}a:hover{color:#fff}a:active:after{background-color:#002d72;top:0}hr{border:1px solid #d5d0c0}div#app{margin:0 10%;padding-bottom:50px}.myname{font-family:factoria,sans-serif;font-size:30pt;font-weight:700;margin:30px 0 35px}div#profile{display:inline-block;max-width:calc(100% - 300px);padding:0 20px;vertical-align:top}@media (max-width:800px){div#profile{max-width:none;padding:initial}}img#profile-pic{padding:15px 0;width:220px}div#projects h3 .subtitle{display:flex;font-size:12pt;font-weight:400;justify-content:space-between}div#projects div.link,div#pubs div.link{display:inline;margin-right:5px}div#projects img,div#pubs img{width:100px}div#projects .contents,div#pubs .contents{display:inline-block;margin-left:20px;max-width:calc(100% - 220px);vertical-align:top}@media (max-width:800px){div#projects img,div#pubs img{display:none}div#projects .contents,div#pubs .contents{display:initial;margin-left:0;max-width:none;vertical-align:initial}}.hide{opacity:0;transition:opacity .3s}.hide:hover{opacity:1}</style>
<link rel="stylesheet" href="/custom_assets/entry.rN-gvYVt.css">
<link rel="modulepreload" as="script" crossorigin href="/custom_assets/GDDhglrP.js">
<link rel="prefetch" as="script" crossorigin href="/custom_assets/Dq7-oZYx.js">
<link rel="prefetch" as="script" crossorigin href="/custom_assets/DlAUqK2U.js">
<link rel="prefetch" as="script" crossorigin href="/custom_assets/B6Of3w6k.js">
<script type="module" src="/custom_assets/GDDhglrP.js" crossorigin></script></head><body><div id="__nuxt"><div id="app"><img src="/images/profile.jpg" alt="profile pic" id="profile-pic"><div id="profile"><div class="myname">Allen Peng</div><!--[--><div><span>BSc (Pharm), MSc (Clin Pharm), MPH</span></div><div><span>Email: <a href="mailto:allen.peng08@gmail.com">allen.peng08@gmail.com</a></span></div><div><span>Phone: <a href="tel:+14438012670">443-801-2670</a></span></div><div><span>Quick links: <a href="https://www.linkedin.com/in/allen-peng-yl/" target="_blank">LinkedIn</a></span></div><!--]--></div><!--[--><p><span>Health economist and with 8 years of experience across a national health technology assessment (HTA) agency and global pharmaceutical companies. Proven ability to lead cross-functional teams and align stakeholders across medical, health economics & outcomes research (HEOR), and commercial functions to drive market access strategy. Skilled in cost-effectiveness analysis (CEA), budget impact modeling, and real-world evidence generation using SAS and R, with a strong track record of informing payer decisions and shaping policy. Recognized with Pfizer’s 2023 Global Best Practice Award for accelerating reimbursement and pricing approvals.</span></p><!--]--><hr><div id="projects"><h2>Working Experience</h2><!--[--><div class="project"><h3><div>MSQ Ventures</div><div class="subtitle"><div>Healthcare Analyst Intern</div><div>SEPT. 2025 – PRESENT</div></div></h3><img src="https://static1.squarespace.com/static/5707117b4c2f85d0ea6156e8/t/5e22892ec77df97290309f82/1579321649048/MSQ-logo-hires-2x1.png" loading="lazy"><div class="contents"><ul><!--[--><li><!--[-->Conducted scientific and market due diligence on 50+ biotech firms, including T cell therapy landscape analysis for Swarm Oncology, to identify cross-border partnership and investment opportunities<!--]--></li><li><!--[-->Developed 10+ pitch decks and pipeline evaluations supporting in/out-licensing and fundraising projects across the U.S., China, and Europe<!--]--></li><li><!--[-->Analyzed global biopharma market and capital trends, summarizing insights that informed prospect targeting and client engagement strategies<!--]--></li><!--]--></ul><!--[--><!--]--></div><hr></div><div class="project"><h3><div>Pfizer</div><div class="subtitle"><div>Market Access Manager</div><div>AUG. 2022 – MAY 2024</div></div></h3><img src="https://www.pfizer.com/profiles/pfecpfizercomus_profile/themes/pfecpfizercomus/public/assets/images/logo-blue.svg" loading="lazy"><div class="contents"><ul><!--[--><li><!--[-->Awarded 2023 Global Pfizer Best Practice - Access Acceleration for CIBINQO®<!--]--></li><li><ul><!--[--><li>Led access strategy that achieved reimbursement and pricing approval 6 months ahead of standard timeline, through close collaboration with global HEOR, commercial, medical, and public affairs teams</li><li>Secured listing price premiums through cost-effectiveness modeling, demonstrating compelling economic value to the national payer</li><!--]--></ul></li><li><!--[-->Led cross-functional and external stakeholder alignment across regulatory, medical, commercial, and advocacy partners, ensuring launch readiness and public awareness for new immunology products and PCV20<!--]--></li><li><!--[-->Expanded reimbursement scope of atopic dermatitis by crafting value propositions that integrated unmet needs and clinical evidence, successfully negotiating with the national payer to broaden patient access<!--]--></li><li><!--[-->Developed simulation models to assess financial impact of biosimilar-favoring policies, enabling proactive mitigation strategies to protect branded biologics portfolio positioning<!--]--></li><!--]--></ul><!--[--><!--]--></div><hr></div><div class="project"><h3><div>Novartis</div><div class="subtitle"><div>Senior Patient Access Specialist</div><div>APR. 2020 – AUG. 2022</div></div></h3><img src="https://www.novartis.com/themes/custom/polaris/logo.svg" loading="lazy"><div class="contents"><ul><!--[--><li><!--[-->Developed CEA and pricing models across cardiovascular and respiratory portfolios, including Enerzair® , where the strategy led to a 2% price markup approved by the national payer<!--]--></li><li><!--[-->Conducted real-world outcomes research using Taiwan’s nationwide claims database (23 million lives) to demonstrate clinical benefits of Entresto® in heart failure care<!--]--></li><li><!--[-->Organized and led International HTA Workshop (100+ attendees), including Director-General and senior officers from the national payer and HTA agency, to strengthen policy dialogue and payer engagement<!--]--></li><li><!--[-->Co-authored policy white papers on cardiovascular disease management, enhancing payer education and disease awareness - &quot;Shaping Cardiovascular Disease Access Policy Landscape&quot;<!--]--></li><!--]--></ul><!--[--><div class="link"> [<a href="https://www.iqvia.com/locations/asia-pacific/library/white-papers/shaping-cvd-policy-landscape-in-taiwan-english" target="_blank">Shaping Cardiovascular Disease Access Policy Landscape</a>] </div><!--]--></div><hr></div><div class="project"><h3><div>Center for Drug Evaluation</div><div class="subtitle"><div>HTA Researcher in Economic Team</div><div>MAR. 2017 – APR. 2020</div></div></h3><img loading="lazy"><div class="contents"><ul><!--[--><li><!--[-->Conducted 20+ CEAs and budget impact analysis annually and authored HTA reports for new drug reimbursement applications, informing payer decisions and enabling access for 600,000+ patients<!--]--></li><li><!--[-->Developed Horizon Scanning system to support national payer in proactive budget planning and allocation<!--]--></li><li><!--[-->Accelerated pneumococcal vaccine policy implementation in high-risk populations by evaluating clinical outcomes and cost-effectiveness, informing national rollout decisions<!--]--></li><li><!--[-->Facilitated Pharmacoeconomics Workshops for pharmaceutical professionals, delivering theoratical and hands-on training on CEA model development using TreeAge and Excel<!--]--></li><li><!--[-->Published HEOR studies and presented findings at international conferences (HTAsiaLink, ISPOR Asia), showcasing analytical and effective scientific communication.<!--]--></li><!--]--></ul><!--[--><!--]--></div><hr></div><div class="project"><h3><div>Kaohsiung Chang Gung Memorial Hospital</div><div class="subtitle"><div>Assistant Researcher</div><div>SEPT. 2016 – MAR. 2017</div></div></h3><img loading="lazy"><div class="contents"><ul><!--[--><li><!--[-->Performed real-world data analysis using SAS on hospital electronic medical records (EMR), including data cleaning, regression modeling, and statistical interpretation<!--]--></li><li><!--[-->Authored a propensity-score matched cohort study examining renal protection effects of medications hyperuricemia patients, contributing to evidence-based clinical recommendations<!--]--></li><li><!--[-->Conducted EQ-5D interviews with pediatric CKD patients as part of a quality-of-life study, also leading IRB submission preparations and developing study protocol to ensure ethical and methodological rigor<!--]--></li><li><!--[-->Participated in the national EQ-5D-5L validation study in Taiwan (Lin et al., 2018), assisting with survey implementation and data quality monitoring across diverse population groups<!--]--></li><!--]--></ul><!--[--><!--]--></div><hr></div><!--]--></div><div id="pubs"><h2>Selected Publications</h2><!--[--><div class="project"><h3>Comparison of uric acid reduction and renal outcomes of febuxostat vs allopurinol in patients with CKD</h3><div class="contents"><div><a>Yueh-Lung Peng</a>, You-Lin Tain, Chien-Te Lee, Yi-Hsn Yang, Yaw-Bin Huang, Yen-Hsia Wen, Chien-Ning Hsu</div><h4>Sci Rep. 2020 Jul 1;10(1):10734</h4><div class="link"> [<a>Show abstract </a>] </div><!--[--><div class="link"> [<a href="https://pubmed.ncbi.nlm.nih.gov/32612180/" target="_blank">Full Text</a>] </div><!--]--><!----></div><hr></div><div class="project"><h3>The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice</h3><div class="contents"><div><a>Yueh-Lung Peng</a>, Chien-Te Lee, You-Lin Tain, Yaw-Bin Huang, Hung-Yi Chuang , Yen-Hsia Wen, Shiou-Huei Huang, Chun-Yu Tsai, Chien-Ning Hsu</div><h4>PLoS One. 2019 Aug 26;14(8):e0221504</h4><div class="link"> [<a>Show abstract </a>] </div><!--[--><div class="link"> [<a href="https://pubmed.ncbi.nlm.nih.gov/31449565/" target="_blank">Full Text</a>] </div><!--]--><!----></div><hr></div><div class="project"><h3>Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin</h3><div class="contents"><div>Ching-Lun Chien, Yen-Chou Chen, Daniel C Malone, <a>Yueh-Lung Peng</a>, Yu Ko</div><h4>Curr Med Res Opin. 2020 Oct;36(10):1619-1626</h4><div class="link"> [<a>Show abstract </a>] </div><!--[--><div class="link"> [<a href="https://pubmed.ncbi.nlm.nih.gov/32851879/" target="_blank">Full Text</a>] </div><!--]--><!----></div><hr></div><!--]--></div></div></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true" data-src="/_payload.json?61f5057a-a3b8-43c4-85fe-5e07202c39e3">[{"state":1,"once":3,"_errors":5,"serverRendered":7,"path":8,"prerenderedAt":9},["Reactive",2],{},["Reactive",4],["Set"],["Reactive",6],{},true,"/",1763328863884]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{gtag:{enabled:true,id:"G-X4R9WJR7YV",initCommands:[],config:{},tags:[],loadingStrategy:"defer",url:"https://www.googletagmanager.com/gtag/js"}},app:{baseURL:"/",buildAssetsDir:"custom_assets",cdnURL:""}}</script></body></html>